Latest Mems News

Page 4 of 5
Memphasys Limited pivots from development to commercial execution with its flagship IVF product Felix, targeting global markets through direct sales and recurring revenue streams.
Ada Torres
Ada Torres
8 Aug 2025
Audio Pixels Holdings reports a delay in its MEMS wafer production due to a key fabrication step requiring revision, while its shares remain suspended on the ASX. The company signals the need for additional funding within six months to sustain its R&D efforts.
Sophie Babbage
Sophie Babbage
31 July 2025
Memphasys Limited has submitted its Felix™ sperm separation system for CE Mark approval, targeting Europe’s $5 billion IVF market, while expanding direct sales in Japan and validating its RoXsta™ oxidative stress diagnostic platform.
Ada Torres
Ada Torres
30 July 2025
Memphasys Limited has submitted its CE Mark application for the Felix™ sperm separation device, targeting regulatory clearance within 6-12 months to unlock the lucrative European IVF market and accelerate approvals in other key regions.
Ada Torres
Ada Torres
30 June 2025
Memphasys Limited has successfully trialed its RoXsta™ Mega Cell High-Throughput Assay, capable of processing 96 antioxidant tests in under an hour, promising a leap forward in rapid, cost-effective oxidative stress analysis.
Ada Torres
Ada Torres
8 May 2025
Memphasys Limited has completed a pivotal Phase III trial confirming its Felix™ System as best-in-class for sperm separation, while advancing regulatory and commercial efforts in China and Brazil supported by fresh capital.
Ada Torres
Ada Torres
30 Apr 2025
Audio Pixels Holdings Limited reports significant progress in its MEMS fabrication and ASIC development, targeting wafer completion by Q2 2025 while managing funding and ASX suspension challenges.
Sophie Babbage
Sophie Babbage
30 Apr 2025
Memphasys has initiated clinical utility testing of its Felix™ System in Brazil through a partnership with Laboratorio Androscience, aiming to establish a foothold in the rapidly growing Latin American IVF sector.
Ada Torres
Ada Torres
17 Feb 2025
Memphasys has completed the final patient visit in its Felix™ clinical trial, with data lock expected within two weeks and preliminary results slated for early March 2025. This milestone paves the way for CE Mark submission and imminent commercialisation in Europe.
Ada Torres
Ada Torres
11 Feb 2025
Audio Pixels Holdings Limited reports significant technical progress in its Digital Sound Reconstruction technology and secures additional funding through convertible notes, while continuing to navigate ASX suspension challenges.
Sophie Babbage
Sophie Babbage
31 Jan 2025
Bluechiip Limited remains in ASX suspension as it finalises its 2024 audited accounts, while its ongoing Strategic Review and BioLife deal set the stage for a pivotal 2025 focused on revenue growth and cash-flow break-even.
Ada Torres
Ada Torres
30 Jan 2025
Bluechiip Limited advances its strategic repositioning with a new licensing agreement valued up to USD 750,000 alongside ongoing efforts to lift its trading suspension and grow sales.
Ada Torres
Ada Torres
30 Jan 2025